Ponnazhagan S - Search Results

1

Anterior gradient protein-2 is a regulator of cellular adhesion in prostate cancer.

Chanda D, Lee JH, Sawant A, Hensel JA, Isayeva T, Reilly SD, Siegal GP, Smith C, Grizzle W, Singh R, Ponnazhagan S. Chanda D, et al. Among authors: ponnazhagan s. PLoS One. 2014 Feb 27;9(2):e89940. doi: 10.1371/journal.pone.0089940. eCollection 2014. PLoS One. 2014. PMID: 24587138 Free PMC article.

2

Adeno-associated virus for cancer gene therapy.

Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD, Siegal GP. Ponnazhagan S, et al. Cancer Res. 2001 Sep 1;61(17):6313-21. Cancer Res. 2001. PMID: 11522617 Review. No abstract available.

3

Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor.

Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE, Meleth S. Ponnazhagan S, et al. Cancer Res. 2004 Mar 1;64(5):1781-7. doi: 10.1158/0008-5472.can-03-1786. Cancer Res. 2004. PMID: 14996740

4

Anti-angiogenic gene therapy for cancer (review).

Isayeva T, Kumar S, Ponnazhagan S. Isayeva T, et al. Among authors: ponnazhagan s. Int J Oncol. 2004 Aug;25(2):335-43. Int J Oncol. 2004. PMID: 15254730 Review.

5

Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.

Mahendra G, Kumar S, Isayeva T, Mahasreshti PJ, Curiel DT, Stockardt CR, Grizzle WE, Alapati V, Singh R, Siegal GP, Meleth S, Ponnazhagan S. Mahendra G, et al. Among authors: ponnazhagan s. Cancer Gene Ther. 2005 Jan;12(1):26-34. doi: 10.1038/sj.cgt.7700754. Cancer Gene Ther. 2005. PMID: 15359287

6

Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.

Isayeva T, Ren C, Ponnazhagan S. Isayeva T, et al. Among authors: ponnazhagan s. Clin Cancer Res. 2005 Feb 1;11(3):1342-7. Clin Cancer Res. 2005. PMID: 15709207

7

Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.

Isayeva T, Ren C, Ponnazhagan S. Isayeva T, et al. Among authors: ponnazhagan s. Gene Ther. 2007 Jan;14(2):138-46. doi: 10.1038/sj.gt.3302853. Epub 2006 Aug 31. Gene Ther. 2007. PMID: 16943851

8

Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.

Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Isayeva T, et al. Among authors: ponnazhagan s. Cancer Res. 2007 Jun 15;67(12):5789-97. doi: 10.1158/0008-5472.CAN-06-3637. Cancer Res. 2007. PMID: 17575146

9

Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma.

Katkoori VR, Jia X, Chatla C, Kumar S, Ponnazhagan S, Callens T, Messiaen L, Grizzle WE, Manne U. Katkoori VR, et al. Among authors: ponnazhagan s. Front Biosci. 2008 Jan 1;13:1050-61. doi: 10.2741/2742. Front Biosci. 2008. PMID: 17981610 Free PMC article.

10

Therapeutic potential of genetically modified mesenchymal stem cells.

Kumar S, Chanda D, Ponnazhagan S. Kumar S, et al. Among authors: ponnazhagan s. Gene Ther. 2008 May;15(10):711-5. doi: 10.1038/gt.2008.35. Epub 2008 Mar 20. Gene Ther. 2008. PMID: 18356815 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

119 results

Search Page